Upcoming Events

CONFERENCES & CONGRESSES

2024 Conference Schedule Coming Soon

Planning to attend? Email us to connect with the team: Maggie Stauber ([email protected])

REGIONAL EDUCATIONAL EVENTS

More Events Coming Soon

If you would like to participate in an upcoming Regional Educational Event, please email Maggie Stauber ([email protected])

ON DEMAND EVENTS

Key Opinion Leader Webinar on Assessing Ovarian Cancer Risk with OvaWatch^℠. Featuring Dr. Leo Twiggs and Dr. Andrew Bokor

PRECAUTION: OvaWatch is intended for use as a non-invasive test to assess the risk of ovarian cancer for women with adnexal masses, evaluated by initial clinical assessment (ICA) as indeterminate or benign.  In conjunction with imaging (ultrasound and/or CT) and clinical assessment, this test will support physicians in making informed clinical decisions in the management of women with adnexal masses. The test is not intended as a screening test or a stand-alone diagnostic assay. Ova1® and Overa® should not be used without an independent clinical and imaging evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

The Balancing Act: Management of Risk Assessment for Ovarian Cancer – Featuring Aspira's CEO, Nicole Sandford, and Axia's Dr. Gerard Reilly

PRECAUTION: OvaWatch is intended for use as a non-invasive test to assess the risk of ovarian cancer for women with adnexal masses, evaluated by initial clinical assessment (ICA) as indeterminate or benign.  In conjunction with imaging (ultrasound and/or CT) and clinical assessment, this test will support physicians in making informed clinical decisions in the management of women with adnexal masses. The test is not intended as a screening test or a stand-alone diagnostic assay. Ova1® and Overa® should not be used without an independent clinical and imaging evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

A Path to Equity: The Impact of Health Disparities in Ovarian Cancer Care

PRECAUTION: Ova1® and Overa® should not be used without an independent clinical and imaging evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.